US go-ahead to lift Ajanta Pharma

Dahej plant was set up in 2014 to meet Ajanta's requirements for the US and emerging markets

Ram Prasad Sahu  |  Mumbai 

The Ajanta Pharma stock was up nearly a per cent after the US Federal Drug Administration (FDA) cleared the company’s Dahej plant in Gujarat. The company informed the exchanges that the US FDA inspected its formulation facility last week and cleared it without issuing any Form 483 observations. The Dahej plant is one of the relatively newer plants of Ajanta Pharma set up in 2014 to meet its requirements for the US and emerging markets.  The approval is critical for the company as the US is its fastest-growing geography. Though, of the overall Rs 2,000-crore revenue ...

TO READ THE FULL STORY, SUBSCRIBE NOW AT JUST Rs 149 A MONTH

Key stories on business-standard.com are available to premium subscribers only.

LOGIN

EMAIL / USER NAME
PASSWORD
REMEMBER ME Forgot password?
LOGIN

Not a member yet ? Resister Now

Connect using any below

  • Don't lose the opportunity of saving $26.77 per month
  • Don't lose the opportunity of saving $26.77 per month
Total Amount
Rs. 0.00
To proceed, kindly select a subscription package

WHAT YOU GET

On Business Standard Digital

  • Access your subscription from anywhere. Be it your computer, tablet or smartphone using a browser or the App, Your Choice.
  • Access to exclusive content, features, opinions and comment, hand-picked by our editors, just for you.
  • Pick your 5 favourite companies. Get all the news upates at the end of each day through E-Mail.
  • Pick the industry that you want to track. And get a daily news letter specific to that industry. Cut out the clutter.
  • And stay on top of your investments. Track stock prices in your portfolio
  • Access 18 years of archival data

On Digital

  • Seamless access to WSJ.com with your Business Standard digital account.
  • Experience the best of the Journal's reporting, video and interactive features.
  • Read about the people and events shaping business, finance, technology, politics, technology and culture.
  • Stay informed with newsletters - an easy way to get WSJ content straight to your inbox - making life easier on your busiest days.
  • More business executives read the Journal globally than any other publication.
*Note :
Our Partners are proud to be associated with this initiative and will contribute Rs 100 x 6 months thereafter, standard rate of Rs 149 will be charged.
Offer valid for Indian residents only
Requires you to share personal information like PAN, Date of Birth, and Income.
*Annual saving on WSJ subscription price of US$ 347.88 (12 months @ US$ 28.99 per month)
* 1US$ = 67.50 INR.
*Please note that this offer is not valid if you are/were a registered/existing user on WSJ Digital

US go-ahead to lift Ajanta Pharma

Dahej plant was set up in 2014 to meet Ajanta's requirements for the US and emerging markets

The Ajanta Pharma stock was up nearly a per cent after the US Federal Drug Administration (FDA) cleared the company's Dahej plant in Gujarat. The company informed the exchanges that the US FDA inspected its formulation facility last week and cleared it without issuing any Form 483 observations. The Dahej plant is one of the relatively newer plants of Ajanta Pharma set up in 2014 to meet its requirements for the US and emerging markets. The approval is critical for the company as the US is its fastest-growing geography. Though, of the overall ~2,000-crore revenue estimated for FY17, the US will account for just 10 per cent or about ~200 crore, it is crucial for driving future growth. Tushar Manudhane of Motilal Oswal Securities believes the company will grow its US business by 46 per cent annually during FY17-20. This is because the company, which has so far filed 32 abbreviated new drug applications (ANDAs), intends to file 12-15 ANDAs annually from FY18. Among the key products are ... The Ajanta Pharma stock was up nearly a per cent after the US Federal Drug Administration (FDA) cleared the company’s Dahej plant in Gujarat. The company informed the exchanges that the US FDA inspected its formulation facility last week and cleared it without issuing any Form 483 observations. The Dahej plant is one of the relatively newer plants of Ajanta Pharma set up in 2014 to meet its requirements for the US and emerging markets.  The approval is critical for the company as the US is its fastest-growing geography. Though, of the overall Rs 2,000-crore revenue ... image
Business Standard
177 22